Exencial Wealth Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Exencial Wealth Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,045	Closed	-$291K	–	456
2023 Q1	$291K	Buy	+9,045	New	+$282K	0.02%	360
2022 Q4	–	Sell	-9,045	Closed	-$244K	–	440
2022 Q3	$244K	Buy	+9,045	New	+$183K	0.01%	364
2021 Q4	–	Sell	-40,555	Closed	-$1.13M	–	484
2021 Q3	$1.13M	Hold	40,555	–	–	0.05%	182
2021 Q2	$1.2M	Hold	40,555	–	–	0.07%	218
2021 Q1	$1.13M	Sell	40,555 -1,075	-3%	-$29.7K	0.07%	206
2020 Q4	$1.18M	Buy	41,630 +14,636	+54%	+$379K	0.08%	183
2020 Q3	$679K	Buy	26,994 +200	+0.7%	+$5.24K	0.04%	230
2020 Q2	$654K	Buy	26,794 +462	+2%	+$9.12K	0.06%	202
2020 Q1	$390K	Buy	26,332 +100	+0.4%	+$2.07K	0.07%	167
2019 Q4	$426K	Buy	26,232 +350	+1%	+$5.43K	0.07%	183
2019 Q3	$336K	Buy	25,882 +15,532	+150%	+$190K	0.07%	183
2019 Q2	$134K	Hold	10,350	–	–	0.03%	224
2019 Q1	$163K	Sell	10,350 -2,500	-19%	-$43.4K	0.04%	221
2018 Q4	$259K	Hold	12,850	–	–	0.07%	182
2018 Q3	$319K	Sell	12,850 -2,894	-18%	-$78.7K	0.07%	143
2018 Q2	$432K	Buy	15,744 +1,000	+7%	+$30.1K	0.12%	122
2018 Q1	$454K	Buy	14,744 +1,100	+8%	+$35.4K	0.14%	119
2017 Q4	$488K	Buy	+13,644	New	+$392K	0.15%	116

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exencial Wealth Advisors's RVNC Position: Q2 2023 in Review

Exencial Wealth Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 9,045 shares — an estimated $291K sold.

Exencial Wealth Advisors first reported a position in RVNC in Q4 2017 and held it in 18 quarters. The position peaked at $1.2M in Q2 2021. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

Exencial Wealth Advisors reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Exencial Wealth Advisors sold 9,045 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $291K.
Exencial Wealth Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 18 quarters.
Exencial Wealth Advisors's Revance Therapeutics, Inc. position peaked at $1.2M in Q2 2021.
215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on Exencial Wealth Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.